Hostname: page-component-7c8c6479df-24hb2 Total loading time: 0 Render date: 2024-03-29T14:10:47.443Z Has data issue: false hasContentIssue false

The informed consent not to be informed - a cross sectional survey on the use of placebo in clinical practice

Published online by Cambridge University Press:  16 April 2020

U. Nitzan
Affiliation:
Outpatient Clinic, Shalvata Mental Health Center, Hod-Hashron, Israel
K. Feffer
Affiliation:
Outpatient Clinic, Shalvata Mental Health Center, Hod-Hashron, Israel
P. Lichtenberg
Affiliation:
Psychiatric Open Ward, Hertzog Hospital, Jerusalem, Israel School of Medicine, Hebrew University, Jerusalem, Israel
S. Lev-Ran
Affiliation:
Outpatient Clinic, Shalvata Mental Health Center, Hod-Hashron, Israel
G. Becker
Affiliation:
Outpatient Clinic, Shalvata Mental Health Center, Hod-Hashron, Israel
S. Fennig
Affiliation:
Outpatient Clinic, Shalvata Mental Health Center, Hod-Hashron, Israel School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Current clinical practice excludes placebo usage on ethical grounds. No attempt was made to clarify the viewpoint of the general population regarding the matter.

Objective

To evaluate the opinion of young-adults towards the use of Placebo in clinical practice.

Aim

  1. 1) Investigate the willingness of our study population to receive placebo for the treatment of depression or other general medical conditions, and

  2. 2) assess whether prescribing placebo would affect the study population's view regarding doctor-patient relationship or patient's autonomy.

Method

We enrolled 344 students from five academic institutes in Israel, and briefed them thoroughly about the effects of placebo, its efficacy and limitations in treating depression. Understanding was verified and only then did the subjects complete a 32 item self-report questionnaire (include sociodemographic, health related data, past experience in medical encounters and willingness of subjects to be treated with Placebo medication).

Results

In contrast to our main hypothesis 70% (N = 243) of the subjects expressed consent to be treated with placebo as a first line treatment had they suffered from depression, and 73% (N = 248) agreed to receive placebo for other general medical conditions. Eighty-eight percent of the subjects (N = 297) did not perceive a physician using placebo as a deceiver or the act of prescribing it a deceit.

Conclusions

The majority of our study population was willing to use placebo medication in general, and in particular, as first line treatment for depression. This study results should promote physicians to rethink and discuss the legitimacy of using placebo in clinical practice.

Type
P02-160
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.